Method To Identify Specific Inhibiutors Of Imp Dehydrogenase
- Bolingbrook, IL
- LaGrange, IL
This invention relates to methods to identify specific inhibitors of the purine nucleotide synthesis enzyme, IMP dehydrogenase (IMPDH). IMPDH is an essential enzyme found in all free-living organisms from humans to bacteria and is an important therapeutic target. The invention allows the identification of specific inhibitors of any IMPDH enzyme which can be expressed in a functional form in a recombinant host cell. A variety of eukaryotic or prokaryotic host systems commonly used for the expression of recombinant proteins are suitable for the practice of the invention. The methods are amenable to high throughput systems for the screening of inhibitors generated by combinatorial chemistry or other methods such as antisense molecule production. Utilization of exogenous guanosine as a control component of the methods allows for the identification of inhibitors specific for IMPDH rather than other causes of decreased cell proliferation.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States)
- DOE Contract Number:
- W-31-109-ENG-38
- Assignee:
- The University of Chicago (Chicago, IL)
- Patent Number(s):
- US 6,153,398
- Application Number:
- 08/997758
- OSTI ID:
- 879487
- Country of Publication:
- United States
- Language:
- English
Cloning, sequence analysis and expression of the group A streptococcal guaB gene encoding inosine monophosphate dehydrogenase
|
journal | January 1995 |
Characterization of human type I and type II IMP dehydrogenases.
|
journal | December 1993 |
Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli
|
journal | September 1988 |
Similar Records
Differential signatures of bacterial and mammalian IMP dehydrogenase enzymes.
Myricetin is a novel inhibitor of human inosine 5′-monophosphate dehydrogenase with anti-leukemia activity